Tripos Announces Chemistry Collaboration with Abbott
News Mar 21, 2006
Tripos, Inc. has announced a chemistry collaboration with Abbott to design, synthesize and purify high-quality, novel, drug-like compounds to expand Abbott’s compound file collection. Tripos and Abbott will collaborate in library design, analysis and synthesis.
"The success of high-throughput technologies in pharmaceutical research is highly dependent on the close coupling of informatics and experimental science," said Dr. John P. McAlister, president and chief executive officer of Tripos.
"With its fully integrated, information-driven chemistry operations, including cutting-edge ChemCore™ and ChemSpace® technologies, Tripos is positioned to add value to the chemical libraries delivered to Abbott."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE